My opinion is different ... $9.95 per share based on peer analysis ...
US-based peers in precision oncology are trading on average at ~ triple the market cap.
RAC's drug has greater maturity in terms of trials history and unquestionably a larger market opportunity do to the huge range of potential synergies and First-in-class and Best-in-class status for FTO.
There is some catching up to do as I think RAC is under-valued based on peer analysis.
Ann: Race Oncology Share Purchase Plan Opens, page-209
-
- There are more pages in this discussion • 349 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |